

Congrès ECCO / ESMO 2015

Présentations orales

- Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc) - Speaker: N. Penel
- Time interval (TI) between surgery and start of adjuvant radiotherapy (RT): A retrospective analysis of 1150 cases from the French Sarcoma Group - Speaker: J. Fourquet
- Reporting adverse events (AEs) in cancer surgery randomized trial: A systemic analysis of published trials in oesogastric (OG) and gynecological (GY) cancer patients - Speaker: M Meghelli

Communications affichées

- A non-interventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma (STS): The first interim analysis of Y-IMAGE study - N. Penel, A. Buonadonna, C. Benson, J. Casanova, B. Kasper, J.A. Nadal, A. López Pousa, F. Mazzeo, T. Brodowicz
- Survival benefit, safety, and prognostic factors for outcome with Regorafenib (REG) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study - C de la Fouchardière, B Paule, P Burtin, J Wallet, D Tougeron, LM Dourthe, PL Etienne, L Mineur, C Becuwe, P Maes, J Dauba, P Michel, JL Wendling, B Linot, A Hollebecque, S Clisant, JF Morere, T André, JM Phelip, A Adenis
- Dose-seeking phase I trials (DSPT) of approved molecularly targeted therapies (MTT): Exhaustiveness and readability of published clinical reports S. Cousin, A. et al
- Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma A. Ducoulombier, et al
- Blood vessel endothelial activation, egfl7 expression, and inflammatory infiltrate in breast cancer, D. Pannier, et al
- Prognostic score (REGOSCORE) for survival after Regorafenib (RE) treatment for patients (pts) with pretreated metastatic colorectal cancer (mCRC) A. Kramar, et al
- Intraperitoneal (IP) chemotherapy (CT) in epithelial ovarian cancer (EOC): A matched case-control study N. Kotecki, et al.
- Safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Data from the ANTHALYA trial, F. Selle, S. Gouy, E. Lambaudie, F. Guyon, V. Fourchette, C. Pomel, P.E. Colombo, E. Kalbacher, S. Martin-Francoise, R. Fauvet, P. Follana, A. Lesoin, F. Lecuru, V. Menguy, Y. Ghazi, E. Chereau, S. Zohar, P. Cottu, F. Joly, R. Rouzier
- Circulating tumor cells kinetics in ovarian carcinoma: correlation with baseline characteristics and CA-125 levels in the randomized ANTHALYA trial evaluating bevacizumab in the neoadjuvant setting, P. Cottu, T. De La Motte Rouge, P. Pautier, M. Provansal, A. Floquet, F. Selle, M.A. Mouret-Reynier, M. Fabbro, E. Kalbacher, C. Piprot, P. Follana, A. Lesoin, J. Medioni, V. Menguy, Y. Ghazi, F.C. Bidard, C. Dubot, F. Joly
- Is PROSIGNA useful to determine adjuvant treatment in intermediate prognosis early breast cancer (EBC)?, J. Bonnetterre, A. Prat, P. Galvan, S. Giard
- Special Session: Stereotactic Hypofractionated Radiation Therapy for Oligometastatic Disease: For Whom and When?

Chair: E. Lartigau